Giant Biogene
Giant Biogene is a synthetic-biology firm making proprietary recombinant collagen matching human amino-acid sequences for Chinese functional-skincare and medical-device consumers.
- Public company
- Xi'an, Shaanxi, CNChina
Giant Biogene is a synthetic-biology firm making proprietary recombinant collagen matching human amino-acid sequences for Chinese functional-skincare and medical-device consumers.
xajuzi.comCrawled Nov 9, 2026
The company produces skincare products under the KefuMei brand, focusing on bioactive ingredients like recombinant collagen protein and rare ginseng saponins.
The company produces skincare products under the KeliJin brand, focusing on bioactive ingredients like recombinant collagen protein and rare ginseng saponins.
Juzichu designs, develops, and produces recombinant collagen protein, rare ginseng saponins, and other bioactive ingredients using proprietary synthetic biology technology. The company focuses on skincare products, medical devices, functional foods, and special medical-purpose formula foods.
The company operates eight brands, including KefuMei, KeliJin, Keyu, Keyin, KefuPing, Liyan, Xingan, and Shengan, specializing in skincare and medical products.
Giant Biogene Holding Co., Ltd. releases its financial performance for the full year ended December 31, 2025. The report outlines key earnings metrics and operational highlights for the biotech firm. Investors and stakeholders await details on revenue growth, profitability, and strategic initiatives.
Mar 2026MarketScreenerNews article
Giant Biogene Holding Co. Ltd. reports strong interim financial performance for 2025. The company highlights positive financial metrics in its latest announcement, though specific details remain undisclosed.
Aug 2025TipRanksNews article
Bloomage Biotech accuses rival **Giant Biogene** of false advertising in a skincare patent dispute. The legal battle has drawn significant attention in China, escalating tensions between the two companies. Bloomage alleges Giant Biogene misrepresented product claims in their skincare formulations, though no resolution has been reached.
Jun 2025Bamboo WorksNews article
China’s **Giant Biogene** secures **$301 million** through a Hong Kong share placement, as confirmed by a term sheet. The funding follows a top-up offering, though specific use cases or investor details remain undisclosed. The company continues its capital-raising efforts amid growth in biotech financing.
Apr 2025ReutersNews article